Minerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

WALTHAM, Mass., 2018-02-05 14:30 CET (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused
on the development of therapies to treat central nervous system (CNS)
disorders, today announced that Dr. Rémy Luthringer has been appointed as
Executive Chairman of Minerva's Board of Directors and William Doyle has been
appointed as Lead Independent Director. 

Dr. Luthringer, as Executive Chairman of the Board and Chief Executive Officer
of Minerva, will continue his close involvement with Minerva's R&D team in the
execution of five late stage clinical trials with three molecules.  Dr.
Luthringer will also lead the implementation of Minerva's commercial strategy,
initially focused on Minerva's lead molecule, MIN-101, currently in Phase 3
clinical testing for the treatment of negative symptoms in patients suffering
from schizophrenia. 

William Doyle, a current director of Minerva, is the Executive Chairman of
Novocure Ltd. (NASDAQ:NVCR), a commercial stage oncology company pioneering a
novel therapy for solid tumors.  "Bill's deep industry experience in strategic
development, partnering, product launches, marketing and commercialization will
benefit Minerva as the foundation is laid for the commercialization of its lead
product candidate, MIN-101, and its other clinical stage assets," said Dr.
Fouzia Laghrissi-Thode, a director of Minerva. 

Marc Beer has resigned as Chairman of Minerva's Board of Directors to pursue
new opportunities. During his tenure over the past four years, he guided
Minerva from a private company through its initial public offering and growth
into late-stage clinical development.  "We would like to thank Marc Beer for
his valuable contributions during the past four years," said Dr. Luthringer. 
"We wish him well in his future endeavors." 

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in Phase
3 clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in Phase 2b clinical development for insomnia and major
depressive disorder (MDD); MIN-117, planned to begin Phase 2b clinical
development for MDD in early 2018; and MIN-301, in pre-clinical development for
Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global
Market under the symbol "NERV."  For more information, please visit
www.minervaneurosciences.com. 

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
as amended.  Forward-looking statements are statements that are not historical
facts, reflect management's expectations as of the date of this press release,
and involve certain risks and uncertainties.  Forward-looking statements
include the timing and outcomes of future interactions with U.S. and foreign
regulatory bodies and statements herein regarding our ability to successfully
develop and commercialize our therapeutic products.  These forward-looking
statements are based on our current expectations and may differ materially from
actual results due to a variety of factors including, without limitation,
whether our product candidates will advance further in the clinical trials
process and whether and when, if at all, they will receive final approval from
the U.S. Food and Drug Administration or equivalent foreign regulatory agencies
and for which indications; management's ability to successfully achieve its
goals; our ability to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions.  These and other potential
risks and uncertainties that could cause actual results to differ from the
results predicted are more fully detailed under the caption "Risk Factors" in
our filings with the Securities and Exchange Commission, including our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, filed
with the Securities and Exchange Commission on November 6, 2017.  Copies of
reports filed with the SEC are posted on our website at
www.minervaneurosciences.com. The forward-looking statements in this press
release are based on information available to us as of the date hereof, and we
disclaim any obligation to update any forward-looking statements, except as
required by law. 

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
[phone]